413 related articles for article (PubMed ID: 25734904)
1. Impact of TP53 codon 72 and MDM2 SNP 309 polymorphisms in pancreatic ductal adenocarcinoma.
Hori Y; Miyabe K; Yoshida M; Nakazawa T; Hayashi K; Naitoh I; Shimizu S; Kondo H; Nishi Y; Umemura S; Kato A; Ohara H; Inagaki H; Joh T
PLoS One; 2015; 10(3):e0118829. PubMed ID: 25734904
[TBL] [Abstract][Full Text] [Related]
2. MDM2 SNP309 associates with accelerated pancreatic adenocarcinoma formation.
Grochola LF; Müller TH; Bond GL; Taubert H; Udelnow A; Würl P
Pancreas; 2010 Jan; 39(1):76-80. PubMed ID: 19752772
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer.
Zhang X; Miao X; Guo Y; Tan W; Zhou Y; Sun T; Wang Y; Lin D
Hum Mutat; 2006 Jan; 27(1):110-7. PubMed ID: 16287156
[TBL] [Abstract][Full Text] [Related]
4. [The relationship and clinicopathological significance of Numb,MDM2 and p53 expression in human pancreatic cancer].
Sheng W; Dong M; Zhou J; Li X; Liu Q; Dong Q; Li F
Zhonghua Wai Ke Za Zhi; 2014 Sep; 52(9):675-81. PubMed ID: 25410780
[TBL] [Abstract][Full Text] [Related]
5. Association of TP53 and MDM2 polymorphisms with survival in bladder cancer patients treated with chemoradiotherapy.
Shinohara A; Sakano S; Hinoda Y; Nishijima J; Kawai Y; Misumi T; Nagao K; Hara T; Matsuyama H
Cancer Sci; 2009 Dec; 100(12):2376-82. PubMed ID: 19764997
[TBL] [Abstract][Full Text] [Related]
6. Impact of TP53 codon 72 and MDM2 promoter 309 allelic dosage in a Moroccan population with hepatocellular carcinoma.
Ezzikouri S; Essaid El Feydi A; Afifi R; Benazzouz M; Hassar M; Pineau P; Benjelloun S
Int J Biol Markers; 2011; 26(4):229-33. PubMed ID: 22180176
[TBL] [Abstract][Full Text] [Related]
7. [Association of murine double minute 2 and P53 polymorphisms with breast cancer susceptibility].
Wang ML; Xu YX; Qian J; Wang FH
Zhonghua Yu Fang Yi Xue Za Zhi; 2013 Feb; 47(2):124-8. PubMed ID: 23719102
[TBL] [Abstract][Full Text] [Related]
8. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
Dong HJ; Fang C; Fan L; Zhu DX; Wang DM; Zhu HY; Zhuang Y; Miao KR; Liu P; Xu W; Li JY
Int J Cancer; 2012 May; 130(9):2054-61. PubMed ID: 21647873
[TBL] [Abstract][Full Text] [Related]
9. MDM2 SNP 309 and p53 codon 72 polymorphisms are associated with the outcome of oral carcinoma patients receiving postoperative irradiation.
Tu HF; Chen HW; Kao SY; Lin SC; Liu CJ; Chang KW
Radiother Oncol; 2008 May; 87(2):243-52. PubMed ID: 18423915
[TBL] [Abstract][Full Text] [Related]
10. Interaction between p53 codon 72 and MDM2 309T>G polymorphisms and the risk of hepatocellular carcinoma.
Qiu M; Liu Y; Yu X; Qin L; Bei C; Zeng X; Qiu X; Tang B; He S; Yu H
Tumour Biol; 2016 Mar; 37(3):3863-70. PubMed ID: 26476535
[TBL] [Abstract][Full Text] [Related]
11. Impact of MDM2 polymorphism: increased risk of developing colorectal cancer and a poor prognosis in the Tunisian population.
Chaar I; Arfaoui TA; El Amine el HO; Mahmoud LB; Khiari M; Sammoud S; Lounis A; Amara S; Gharbi L; Hmida AB; Mzabi S; Bouraoui S
Eur J Gastroenterol Hepatol; 2012 Mar; 24(3):320-7. PubMed ID: 22266832
[TBL] [Abstract][Full Text] [Related]
12. MDM2 rs2279744 and TP53 rs1042522 polymorphisms associated with etoposide- and cisplatin-induced grade III/IV neutropenia in Chinese extensive-stage small-cell lung cancer patients.
Wang X; Wang YZ; Ma KW; Chen X; Li W
Oncol Res Treat; 2014; 37(4):176-80. PubMed ID: 24732641
[TBL] [Abstract][Full Text] [Related]
13. Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients.
Toyama T; Zhang Z; Nishio M; Hamaguchi M; Kondo N; Iwase H; Iwata H; Takahashi S; Yamashita H; Fujii Y
Breast Cancer Res; 2007; 9(3):R34. PubMed ID: 17537232
[TBL] [Abstract][Full Text] [Related]
14. A single-nucleotide polymorphism in the TP53 and MDM-2 gene modifies breast cancer risk in an ethnic Arab population.
Alshatwi AA; Hasan TN; Shafi G; Alsaif MA; Al-Hazzani AA; Alsaif AA
Fundam Clin Pharmacol; 2012 Jun; 26(3):438-43. PubMed ID: 21477265
[TBL] [Abstract][Full Text] [Related]
15. Elevated transcript levels from the MDM2 P1 promoter and low p53 transcript levels are associated with poor prognosis in human pancreatic ductal adenocarcinoma.
Grochola LF; Taubert H; Greither T; Bhanot U; Udelnow A; Würl P
Pancreas; 2011 Mar; 40(2):265-70. PubMed ID: 21404460
[TBL] [Abstract][Full Text] [Related]
16. Investigation of the effect of MDM2 SNP309 and TP53 Arg72Pro polymorphisms on the age of onset of cutaneous melanoma.
Cotignola J; Chou JF; Roy P; Mitra N; Busam K; Halpern AC; Orlow I
J Invest Dermatol; 2012 May; 132(5):1471-8. PubMed ID: 22336942
[TBL] [Abstract][Full Text] [Related]
17. Impact of
Wujcicka W; Zając A; Stachowiak G
In Vivo; 2019; 33(3):917-924. PubMed ID: 31028217
[TBL] [Abstract][Full Text] [Related]
18. The clinicopathological significance and relationship of Gli1, MDM2 and p53 expression in resectable pancreatic cancer.
Sheng W; Dong M; Zhou J; Li X; Liu Q; Dong Q; Li F
Histopathology; 2014 Mar; 64(4):523-35. PubMed ID: 24289472
[TBL] [Abstract][Full Text] [Related]
19. Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups.
van den Broek AJ; Broeks A; Horlings HM; Canisius SV; Braaf LM; Langerød A; Van't Veer LJ; Schmidt MK
Breast Cancer Res Treat; 2011 Nov; 130(2):599-608. PubMed ID: 21667122
[TBL] [Abstract][Full Text] [Related]
20. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
